Literature DB >> 30947761

Caffeine and blood pressure: a critical review perspective.

Rachele De Giuseppe1, Ilaria Di Napoli1, Francesca Granata2, Antonia Mottolese3, Hellas Cena1,4.   

Abstract

The WHO reported that high blood pressure (BP) is one of the primary causes of death worldwide. Hypertension (HPT) is a major risk factor for CVD and related diseases as well as for diseases, leading to a considerable increase in cardiovascular risk. Since BP response could also be influenced by caffeine, which is widely consumed with coffee and other items, it is important to define the possible effects associated with caffeine intake. The most recent findings aimed at clarifying the role of caffeine consumption on BP and HPT risk/incidence are conflicting and difficult to interpret. Therefore, in the present narrative review, we aimed to examine various methodological inaccuracies/aspects and factors that make studies difficult to be compared, in order to obtain a single consensus on the effects of caffeine intake on the risk of BP and HPT. We observed that this heterogeneity in results could be due to the presence of: (i) several variables affecting BP (such as age, sex, genetic and lifestyle aspects); (ii) different caffeine content of food and beverages; and (iii) caffeine metabolism. Moreover, different methodological aspects in the evaluation of daily dietary caffeine intake and in the BP measurement could add some other bias in the interpretation of results. Therefore, it is mandatory to consider all methodological aspects and confounding factors to generate a standardised methodology in order to increase cross-study consistency and minimise confounding effects of different variables on the relationship between BP response and HPT risk/incidence after caffeine intake.

Entities:  

Keywords:  Blood pressure; Caffeine; Hypertension; Methodology

Year:  2019        PMID: 30947761     DOI: 10.1017/S0954422419000015

Source DB:  PubMed          Journal:  Nutr Res Rev        ISSN: 0954-4224            Impact factor:   7.800


  6 in total

1.  Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications.

Authors:  Stefanie N Hinkle; Jessica L Gleason; Samrawit F Yisahak; Sifang Kathy Zhao; Sunni L Mumford; Rajeshwari Sundaram; Jagteshwar Grewal; Katherine L Grantz; Cuilin Zhang
Journal:  JAMA Netw Open       Date:  2021-11-01

2.  Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort).

Authors:  Tangui Barré; Hélène Fontaine; Stanislas Pol; Clémence Ramier; Vincent Di Beo; Camelia Protopopescu; Fabienne Marcellin; Morgane Bureau; Marc Bourlière; Céline Dorival; Ventzislava Petrov-Sanchez; Tarik Asselah; Elisabeth Delarocque-Astagneau; Dominique Larrey; Jean-Charles Duclos-Vallée; Fabrice Carrat; Patrizia Carrieri
Journal:  Antioxidants (Basel)       Date:  2022-02-14

3.  Medical conditions associated with coffee consumption: Disease-trajectory and comorbidity network analyses of a prospective cohort study in UK Biobank.

Authors:  Can Hou; Yu Zeng; Wenwen Chen; Xin Han; Huazhen Yang; Zhiye Ying; Yao Hu; Yajing Sun; Yuanyuan Qu; Fang Fang; Huan Song
Journal:  Am J Clin Nutr       Date:  2022-09-02       Impact factor: 8.472

Review 4.  Fermented foods and cardiometabolic health: Definitions, current evidence, and future perspectives.

Authors:  Katherine J Li; Kathryn J Burton-Pimentel; Guy Vergères; Edith J M Feskens; Elske M Brouwer-Brolsma
Journal:  Front Nutr       Date:  2022-09-20

Review 5.  Current Trends in the Pharmacotherapy of Cataracts.

Authors:  Segewkal H Heruye; Leonce N Maffofou Nkenyi; Neetu U Singh; Dariush Yalzadeh; Kalu K Ngele; Ya-Fatou Njie-Mbye; Sunny E Ohia; Catherine A Opere
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-16

6.  Identification of High-Risk Pregnancies in a Remote Setting Using Ambulatory Blood Pressure: The MINDI Cohort.

Authors:  Doris González-Fernández; Emérita Del Carmen Pons; Delfina Rueda; Odalis Teresa Sinisterra; Enrique Murillo; Marilyn E Scott; Kristine G Koski
Journal:  Front Public Health       Date:  2020-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.